Dual PD-L1 and CTLA-4 blockade in lung cancer (ID 4916)
Emerging evidence for CTLA-4 inhibition in metastatic NSCLC (ID 4917)
Case study: Considerations for new combinations in metastatic NSCLC (ID 4918)
PD-L1 +/- CTLA-4 blockade in SCLC: clinical evidence and future perspectives (ID 4919)
Future perspectives on combined immune blockade in lung cancer (ID 4920)
